Japan’s Healios Eyes First Approvals As It Progresses Regenerative Therapies
Healios, a Japanese regenerative medicine bioventure, expects to continue benefiting from a supportive regulatory environment in Japan as it progresses three clinical assets toward approval in the next few years, says CEO Dr. Hardy Kagimoto in an exclusive interview.
You may also be interested in...
While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and regulators is needed to ensure a reflection of industry and patient concerns, one CEO says.
Japan has formally enacted new legislation governing the development, approval and use of regenerative medicines, including induced pluripotent stem (iPS) cells, in a move welcomed by companies both inside and outside the country.
After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.